Alexandria, VA - A multicenter, Phase III study conducted by researchers at Columbia University Medical Center showed that the osteoporosis drug zoledronic acid (Zometa) prevents bone loss at 12 months in premenopausal women undergoing chemotherapy following surgery for early-stage breast cancer.
Alexandria, VA--Summaries of three studies being published online August 11, 2008 in the Journal of Clinical Oncology show people with cancer are more likely to commit suicide or contemplate taking their own lives, compared to the general population.
Alexandria, Va.—A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse’s cancer was incurable, or they heard this information during the last week of her life. Eighty-six percent of widowers believed next-of-kin should be told immediately when a wife’s cancer is incurable, including 71 percent of the men who did not recall being told this information. The study, which is the largest to explore this topic, is being published online July 10 in the Journal of Clinical Oncology (JCO).
Alexandria, Va.—In the first study to assess mammography in women 80 and older, researchers found that having regular mammograms significantly decreases the risk of being diagnosed with late-stage breast cancer, but only about one-fifth of women in this age group receive them regularly.
Alexandria, Va.—A multicenter phase III clinical trial has reported that the drug letrozole cuts the risk of breast cancer recurrence by 63 percent and the risk of cancer spread by 61 percent in postmenopausal women with early-stage disease who completed five years of tamoxifen therapy one to seven years earlier.
Alexandria, Va.—A multicenter phase III clinical trial has reported that the drug letrozole cuts the risk of breast cancer recurrence by 63 percent and the risk of cancer spread by 61 percent in postmenopausal women with early-stage disease who completed five years of tamoxifen therapy one to seven years earlier. The study is being published online March 10 in the Journal of Clinical Oncology (JCO).
Alexandria, Va.—A new study finds that the cancer risk reduction resulting from the removal of the ovaries and fallopian tubes in women who are at genetically high risk for breast and gynecological cancer varies according to the type of genetic mutation present. The study is being published online February 11 in the Journal of Clinical Oncology (JCO).
Alexandria, VA—Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations.
ALEXANDRIA, VA—Two studies report that exercise and yoga can help maintain and in some cases improve quality of life in women with early-stage breast cancer.
ALEXANDRIA, Va. – A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies.
